CN Patent

CN102088976B — 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品

Assigned to Pulmagen Therapeutics Synergy Ltd · Expires 2012-12-26 · 13y expired

What this patent protects

本发明提供了用于治疗呼吸系统疾病诸如慢性阻塞性肺病和哮喘的药物产品、试剂盒或者组合物，所述药物产品、试剂盒或者组合物包含第一活性成分和第二活性成分，其中第一活性成分为选择的毒蕈碱性受体拮抗剂，以及第二活性成分为β 2 -肾上腺素受体激动剂。

USPTO Abstract

本发明提供了用于治疗呼吸系统疾病诸如慢性阻塞性肺病和哮喘的药物产品、试剂盒或者组合物，所述药物产品、试剂盒或者组合物包含第一活性成分和第二活性成分，其中第一活性成分为选择的毒蕈碱性受体拮抗剂，以及第二活性成分为β 2 -肾上腺素受体激动剂。

Drugs covered by this patent

olodaterol-hydrochloride (OLODATEROL HYDROCHLORIDE)

Patent Metadata

Patent number: CN102088976B
Jurisdiction: CN
Classification: —
Expires: 2012-12-26
Drug substance claim: No
Drug product claim: No
Assignee: Pulmagen Therapeutics Synergy Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.